ClinicalTrials.gg
Active, not recruitingNCT06198374Pro-HealthUpdated Nov 5, 2026

Impact of Propionic Acid on Regulatory T Cell Function in Healthy Adults ( Pro-Health)

An interventional study of Sodium propionate and Placebo in Healthy, sponsored by Charite University, Berlin, Germany. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science

How we know

Updated Nov 5, 2026Study completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Pro-Health is a single-center, double-blind, randomized and placebo-controlled intervention study in healthy adults. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in healhty adults.

Read the detailed description

Chronic inflammation is a major risk factor of cardiovascular disease progression in CKD, irrespective of confounding comorbidities. Based on current knowledge, microbially-derived metabolites such as short chain fatty acids (SCFA) play an important role in the regulation of chronic inflammatory processes in CKD patients. Patients with CKD are known to have reduced serum levels of the SCFA propionic acid (PA), as a consequence of both gut microbial dysbiosis and reduced fiber intake. In animal and human studies the impact of PA on function and abundance of regulatory T cells (Treg) has been demonstrated. Consequently, the investigators aim to increase the PA serum levels by oral PA food supplementation in healthy adults in order to perspectively intervene with the same strategy in patients with CKD in the near future, with the target to increase abundance and function of antiinflammatory cells.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 40 years old
  • Body weight: > 30kg

Exclusion criteria

Exclusion Criteria:

  • Disease or dysfunctions, which disqualifies the patient
  • Incapacity of contract or any other circumstances, which prohibit the patient from understanding setup, meaning and entity of the study
  • Acute infections
  • therapy within the last 12 weeks before the start of the study
  • Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study
  • Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study
  • Malignant diseases
  • Pregnancy
  • chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease
  • alcohol- or drug abuse
  • parallel participation on other interventional trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    PA Intervention.

    The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.

    Dietary Supplement: Sodium propionate

  • Placebo comparator
    Placebo Intervention

    The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.

    Other: Placebo

Interventions

  • Dietary supplementSodium propionate

    The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

    Also known as: Propicum

  • OtherPlacebo

    The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

06

What researchers measure

Primary outcomes

  1. Change in count of regulatory T-cells from baseline to week 4

    Analysis of Treg counts in whole blood (absolute quantification) and peripheral blood

    Time frame: Baseline visit (week 0) in comparison to week 4

Secondary outcomes

  1. Propionic acid serum levels and targeted metabolomics

    Analysis of PA serum levels and other microbially-derived metabolites by GC-MS and LC-MS

    Time frame: Baseline visit (week 0); Week 2; Week 4

  2. Relative abundance of different immune cell subsets with Immune cell phenotyping of peripheral blood mononuclear cells (PBMC)

    Patients PBMC will be thawed and immune cells we be analyzed using multicolor flow cytometry and mass cytometry. By using a broad range of different antibodies combined in several panels the investigators will analyse distinct T cell subtypes including markers of activation, but also other immune cells (including B cells, dendritic cells, monocytes, natural killer cells). Data will reported in relation to parent populations (e.g. T heller cells in % of T cells).

    Time frame: Baseline visit (week 0); Week 2; Week 4

  3. Measuring the suppressive function of regulatory T cells (Tregs) as percentage of proliferated conventional CD4-positive T cells with an in vitro T regulatory cell (Treg) suppression assay

    The suppressive capacity of patients Treg will be analyzed by co-cultivation with conventional, stimulated T cells (Tconv) in different proportions (Treg:Tconv). The proliferation of Tconv will be reported.

    Time frame: Baseline visit (week 0); Week 4

  4. Single cell RNA sequencing of immune cells

    Analysis of the transcriptome of immune cells using cellular indexing of transcriptomes and epitopes (CITEseq)

    Time frame: Baseline visit (week 0); Week 4

  5. Measuring the intestinal barrier function by measuring the concentration of different leaky gut markers

    Analysis of biomarkers for intestinal barrier function, such as sCD14, zonulin-1 and LPS

    Time frame: Baseline visit (week 0); Week 2; Week 4

  6. Taxonomy of the fecal microbiome

    The taxonomy of the fecal microbiome will be anayzed using 16S RNA amplicon sequencing.

    Time frame: Baseline visit (week 0); Week 4

  7. Cardiovascular Phenothyping

    Analysis of heart rate over time.

    Time frame: Baseline visit (week 0); Week 2; Week 4

  8. Cardiovascular Phenotyping

    Analysis of blood pressure over time.

    Time frame: Baseline visit (week 0); Week 2; Week 4

  9. Cholesterol levels

    Cholestrol levels will be assessed using standard clinical lab values

    Time frame: Baseline visit (week 0); Week 2; Week 4

07

Study locations

1 site
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin
    Berlin, State of Berlin 13353, Germany
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Feb 2024, 1 month.

Completion moved once since we started tracking on Sep 25, 2026: May 2025 → Jan 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2023
First posted
Jan 10, 2024
StartActual
Jan 8, 2024
Primary completionActual
Feb 28, 2024
CompletionEst.
Jan 30, 2027was May 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
Show 1 removed
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
Nov 5, 2026
Study completion
May 30, 2025→Jan 30, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
    Show 1 removed
    • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
    Study completion May 30, 2025→Jan 30, 2027
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06198374
Responsible party
Johannes Benjamin Holle (Principal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
Jan 10, 2024
Start date
Jan 8, 2024
Primary completion
Feb 28, 2024
Completion
Jan 30, 2027 (estimated)
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium propionate

Start the discussion